Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 806-813 , July 2007

Economic Impact of Palifermin on the Costs of Hospitalization for Autologous Hematopoietic Stem-Cell Transplant: Analysis of Phase 3 Trial Results

  • Linda S. Elting

      Affiliations

    • University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • Corresponding Author InformationCorrespondence and reprint requests: Linda S. Elting, DrPH, Health Services Research, Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 447, Houston, TX 77030-4009.
    • ,
  • Ya-Chen Tina Shih

      Affiliations

    • University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Patrick J. Stiff

      Affiliations

    • Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, Illinois
    • ,
  • William Bensinger

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Scott B. Cantor

      Affiliations

    • University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Catherine Cooksley

      Affiliations

    • University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • Ricardo Spielberger

      Affiliations

    • City of Hope National Medical Center, Duarte, California
    • ,
  • Christos Emmanoulides

      Affiliations

    • Interbalkan Hospital, Thessaloniki, Greece

Received 6 October 2006 ,Accepted 5 March 2007.

References 

  1. Filicko J, Lazarus HM, Flomenberg N. Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment. Bone Marrow Transplant. 2003;31:1–10
  2. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201–2205
  3. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562–1568
  4. McGuire DB, Altomonte V, Peterson DE, et al. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum. 1993;20:1493–1502
  5. Pico JL, Avila-Garavito A, Naccache P. Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist. 1998;3:446–451
  6. Woo SB, Sonis ST, Monopoli MM, Sonis AL. A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer. 1993;72:1612–1617
  7. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy (Clinical and economic outcomes of chemotherapy-induced mucositis). Cancer. 2003;98:1531–1539
  8. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–2598
  9. Emmanoulides C, Spielberger R, Stiff P, et al. Paliferm treatment of mucositis in transplant patients reduces health resource use: Phase 3 results. Abstracts of the American Society of Hematology 45th Annual Meeting. December 6-9, 2003. San Diego, CA. Blood. 2003;102:Abstract 883
  10. Horsley P, Bauer JD, Mazkowiack R, Gardner R, Bashford J. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer. 2007;15:105–109
  11. Schoenman JA, Sutton JP, Kintala S, Love D, Maw R. In: The Value of Hospital Discharge Databes. Chicago, IL: NORC at the University of Chicago, National Association of Health Data Organizations; 2005;p. 1–102
  12. Statewide average operating cost-to-charge ratios for urban and rural hospitals Federal Register Vol 67, No.148. Thursday, August 1, 2002/Rules and Regulations, p. 50263.
  13. Bureau of Labor Statistics. Consumer Price Index—All Urban Consumers Accessed on Jan 20, 2006 from http://data/bls/gov/cgi-bin/surveymost
  14. Centers for Medicare and Medicaid Services. Medicare Part B Drug Average Sales Price. January 2006. Accessed on February 2, 2006 from http://www.cms.hhs.gov/McrPartBDrugAvgSalesPrice/02_aspfiles.asp#TopOfPage
  15. Sonis ST. Pathobiology of mucositis. Semin Oncol Nurse. 2004;20:11–15
  16. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 1998;82:2275–2281
  17. Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995–2025
  18. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100:2026–2046
  19. Stiff PJ. Oral mucositis therapy comes of age. J Support Oncol. 2005;3:73–75
  20. Stiff PJ, Emmanouilides C, Bensinger WI, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol. 2006;24:5185–5193
  21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383
  22. Karnofsy DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In:  MacLeod CM editors. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949;p. 196

PII: S1083-8791(07)00196-6

doi: 10.1016/j.bbmt.2007.03.004

Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 806-813 , July 2007

Article Tools

* Image Usage & Resolution